{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:01:50Z","timestamp":1792180910375,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-026-01664-7","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:43:27Z","timestamp":1770043407000},"page":"687-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of Obesity in Psoriasis Consultations"],"prefix":"10.1007","volume":"16","author":[{"given":"Joana","family":"Nicolau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2121-963X","authenticated-orcid":false,"given":"Anna","family":"L\u00f3pez-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"1664_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301\u201315.","journal-title":"Lancet"},{"key":"1664_CR2","volume-title":"Global report on psoriasis","author":"WHO","year":"2016","unstructured":"WHO. Global report on psoriasis. Geneva: World Health Organization; 2016."},{"key":"1664_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","volume":"105","author":"JM Carrascosa","year":"2014","unstructured":"Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105:31\u201344.","journal-title":"Actas Dermosifiliogr"},{"key":"1664_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002739","volume":"16","author":"A Budu-Aggrey","year":"2019","unstructured":"Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: a mendelian randomization study. PLoS Med. 2019;16:e1002739.","journal-title":"PLoS Med"},{"key":"1664_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jid.2020.11.025","volume":"141","author":"MT Patrick","year":"2021","unstructured":"Patrick MT, Stuart PE, Zhang H, et al. Causal relationship and shared genetic loci between psoriasis and type\u00a02 diabetes through trans-disease meta-analysis. J Invest Dermatol. 2021;141:1493\u2013502.","journal-title":"J Invest Dermatol"},{"key":"1664_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10654-018-0366-z","volume":"33","author":"D Aune","year":"2018","unstructured":"Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33:1163\u201378.","journal-title":"Eur J Epidemiol"},{"key":"1664_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13679-020-00380-3","volume":"9","author":"K Paroutoglou","year":"2020","unstructured":"Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M. Deciphering the association between psoriasis and obesity: current evidence and treatment considerations. Curr Obes Rep. 2020;9:165\u201378.","journal-title":"Curr Obes Rep"},{"key":"1664_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5114\/aoms.2016.58928","volume":"13","author":"MS Ellulu","year":"2017","unstructured":"Ellulu MS, Patimah I, Khaza\u2019ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13:851\u201363.","journal-title":"Arch Med Sci"},{"key":"1664_CR9","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3390\/ijms20092358","volume":"20","author":"M Longo","year":"2019","unstructured":"Longo M, Zatterale F, Naderi J, et al. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci. 2019;20:2358.","journal-title":"Int J Mol Sci"},{"key":"1664_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","volume":"181","author":"A Mourad","year":"2019","unstructured":"Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181:450\u20138.","journal-title":"Br J Dermatol"},{"key":"1664_CR11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182:840\u20138.","journal-title":"Br J Dermatol"},{"key":"1664_CR12","first-page":"130","volume":"68","author":"MD Ballesteros Pomar","year":"2021","unstructured":"Ballesteros Pomar MD, Vilarrasa Garc\u00eda N, et al. The SEEN comprehensive clinical survey of adult obesity: executive summary. Endocrinol Diabetes Nutr (Engl Ed). 2021;68:130\u20136.","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"24","key":"1664_CR13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"1664_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00011-025-02140-2","volume":"74","author":"S Buonanno","year":"2025","unstructured":"Buonanno S, Gaggiano C, Terribili R, Cantarini L, Frediani B, Gentileschi S. The potential role of GLP-1 receptor agonists in managing psoriatic disease comorbidities. Inflamm Res. 2025;74(1):167.","journal-title":"Inflamm Res"},{"issue":"3","key":"1664_CR15","first-page":"42","volume":"18","author":"W Patino","year":"2025","unstructured":"Patino W, Thomas A, Jain S, Del Rosso JQ, Issa NT. A review of glucagon-like peptide-1 in dermatology. J Clin Aesthet Dermatol. 2025;18(3):42\u201350.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1664_CR16","unstructured":"European Association for the Study of Obesity (EASO). A new framework for the diagnosis, staging and management of obesity in adults. Nature Medicine. 2024. https:\/\/www.seedo.es\/images\/site\/giro\/GUIA-GIRO-2a-edicin_26NOV2024.pdf."},{"key":"1664_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ad.2023.06.017","volume":"115","author":"E Vilarrasa","year":"2024","unstructured":"Vilarrasa E, Nicolau J, de la Cueva P, et al. Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermosifiliogr. 2024;115:56\u201365.","journal-title":"Actas Dermosifiliogr"},{"issue":"11","key":"1664_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2025.106941","volume":"164","author":"J Nicolau","year":"2025","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, et al. Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control? Med Clin (Barc). 2025;164(11):106941.","journal-title":"Med Clin (Barc)"},{"key":"1664_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf473","author":"J Nicolau","year":"2025","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, et al. Dermatologic and metabolic benefits of semaglutide in psoriasis with obesity: a six-month prospective cohort study. Clin Exp Derm. 2025. https:\/\/doi.org\/10.1093\/ced\/llaf473.","journal-title":"Clin Exp Derm"},{"key":"1664_CR20","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192:E875\u201391.","journal-title":"CMAJ"},{"key":"1664_CR21","unstructured":"CUN-BAE Formula: https:\/\/www.onlinetrainer.es\/CUN-BAE.php. Accessed 26 Jan 2026."},{"key":"1664_CR22","doi-asserted-by":"publisher","first-page":"267.e1","DOI":"10.1016\/j.medcli.2019.10.014","volume":"155","author":"A Caix\u00e0s","year":"2020","unstructured":"Caix\u00e0s A, Villar\u00f3 M, Arraiza C, et al. SEEDO-SEMERGEN consensus document on continuous care of obesity between primary care and specialist hospital units 2019. Med Clin (Barc). 2020;155:267.e1-267.e11.","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"1664_CR23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/bjd.17741","volume":"181","author":"SK Mahil","year":"2019","unstructured":"Mahil SK, McSweeney SM, Kloczko E, McGowan B, Barker JN, Smith CH. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic. Br J Dermatol. 2019;181(5):946\u201353.","journal-title":"Br J Dermatol"},{"key":"1664_CR24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","volume":"149","author":"P Jensen","year":"2013","unstructured":"Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149:795\u2013801.","journal-title":"JAMA Dermatol"},{"key":"1664_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.clindermatol.2021.10.005","volume":"40","author":"S Muzumdar","year":"2022","unstructured":"Muzumdar S, Rothe MJ. Nutrition and psoriasis. Clin Dermatol. 2022;40:128\u201334.","journal-title":"Clin Dermatol"},{"key":"1664_CR26","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.clnu.2019.05.006","volume":"39","author":"SK Madden","year":"2020","unstructured":"Madden SK, Flanagan KL, Jones G. How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis. Clin Nutr. 2020;39:1026\u201340.","journal-title":"Clin Nutr"},{"key":"1664_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/jamadermatol.2018.2127","volume":"154","author":"C Phan","year":"2018","unstructured":"Phan C, Touvier M, Kesse-Guyot E, et al. Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the Nutrinet-Sant\u00e9 cohort. JAMA Dermatol. 2018;154:1017\u201324.","journal-title":"JAMA Dermatol"},{"key":"1664_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2020.110757","volume":"74","author":"G Castaldo","year":"2020","unstructured":"Castaldo G, Rastrelli L, Galdo G, Molettieri P, Rotondi Aufiero F, Cereda E. Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: a proof-of-concept, single-arm, open-label clinical trial. Nutrition. 2020;74:110757.","journal-title":"Nutrition"},{"key":"1664_CR29","first-page":"189","volume":"12","author":"S Yeroushalmi","year":"2022","unstructured":"Yeroushalmi S, Hakimi M, Chung M, Bartholomew E, Bhutani T, Liao W. Psoriasis and exercise: a review. Psoriasis (Auckl). 2022;12:189\u201397.","journal-title":"Psoriasis (Auckl)"},{"issue":"10","key":"1664_CR30","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL, et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025;31(10):3229\u201332.","journal-title":"Nat Med"},{"key":"1664_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.joca.2024.03.003","volume":"32","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, et al. Semaglutide 2.4\u00a0mg efficacy and safety in people with obesity and knee osteoarthritis: results from the STEP-9 randomised clinical trial. Osteoarthr Cartil. 2024;32:745\u20136.","journal-title":"Osteoarthr Cartil"},{"issue":"13","key":"1664_CR32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"issue":"21","key":"1664_CR33","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase\u00a03 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"key":"1664_CR34","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","volume":"403","author":"Q Shi","year":"2024","unstructured":"Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024;403:e21-31.","journal-title":"Lancet"},{"key":"1664_CR35","unstructured":"Orlistat: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/78962\/78962_ft.pdf. Accessed 26 Jan 2026."},{"key":"1664_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type\u00a02 diabetes in obese patients. Diabetes Care. 2004;27:155\u201361.","journal-title":"Diabetes Care"},{"key":"1664_CR37","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/dom.12632","volume":"18","author":"J Ard","year":"2016","unstructured":"Ard J, Cannon A, Lewis CE, et al. Efficacy and safety of liraglutide 3.0\u00a0mg for weight management are similar across races: subgroup analysis across the SCALE and phase\u00a0II randomized trials. Diabetes Obes Metab. 2016;18:430\u20135.","journal-title":"Diabetes Obes Metab"},{"key":"1664_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med"},{"key":"1664_CR39","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1664_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"1664_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","volume":"161","author":"J Nicolau","year":"2023","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, Pujol A, Nadal C, Masmiquel L. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023;161:293\u20136.","journal-title":"Med Clin (Barc)"},{"key":"1664_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","volume":"12","author":"JJ Gorgojo-Mart\u00ednez","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12:145.","journal-title":"J Clin Med"},{"key":"1664_CR43","unstructured":"Liraglutide: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/115992002\/FT_115992002.html. Accessed 26 Jan 2026."},{"key":"1664_CR44","unstructured":"Semaglutide: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1211608010\/FT_1211608010.html. Accessed 26 Jan 2026."},{"key":"1664_CR45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989.","journal-title":"N Engl J Med"},{"key":"1664_CR46","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391.","journal-title":"Nat Med"},{"key":"1664_CR47","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"1664_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41366-024-01646-9","volume":"49","author":"AS Cleto","year":"2025","unstructured":"Cleto AS, Schirlo JM, Beltrame M, et al. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Int J Obes (Lond). 2025;49(1):21\u201330.","journal-title":"Int J Obes (Lond)"},{"key":"1664_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.17925\/HI.2024.18.1.1","volume":"18","author":"AJ Binu","year":"2024","unstructured":"Binu AJ, Kapoor N. Cardiovascular implications of semaglutide in obesity management: redefining cardiovascular health strategies. Heart Int. 2024;18:3\u20134.","journal-title":"Heart Int"},{"key":"1664_CR50","first-page":"21\u20130007, EDM210","volume":"2021","author":"G Costanzo","year":"2021","unstructured":"Costanzo G, Curatolo S, Bus\u00e0 B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type\u00a02 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021;2021:21\u20130007, EDM210007.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"1664_CR51","first-page":"23","volume":"2023","author":"AE Malavazos","year":"2023","unstructured":"Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023:23\u20130017.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"1664_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314631","volume":"23","author":"I Forzano","year":"2022","unstructured":"Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G. Tirzepatide: a systematic update. Int J Mol Sci. 2022;23:14631.","journal-title":"Int J Mol Sci"},{"key":"1664_CR53","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","volume":"47","author":"B Tan","year":"2023","unstructured":"Tan B, Pan X-H, Chew HSJ, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes (Lond). 2023;47:677\u201385.","journal-title":"Int J Obes (Lond)"},{"key":"1664_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108332","volume":"36","author":"S Tall Bull","year":"2022","unstructured":"Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: a novel, first-in-class, dual GIP\/GLP-1 receptor agonist. J Diabetes Complications. 2022;36:108332.","journal-title":"J Diabetes Complications"},{"key":"1664_CR55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"1664_CR56","unstructured":"CLINICAL TRIALS: https:\/\/clinicaltrials.gov\/study\/NCT05556512. Accessed 28 Jan 2026."},{"key":"1664_CR57","unstructured":"Tirzepatide: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1221685014\/FT_1221685014.html. Accessed 28 Jan 2026."},{"key":"1664_CR58","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.soard.2024.07.011","volume":"20","author":"A Hosseininasab","year":"2024","unstructured":"Hosseininasab A, Mosavari H, Rostami A, et al. The long-term impact of bariatric surgery on psoriasis symptoms and severity: a prospective observational study. Surg Obes Relat Dis. 2024;20:1208\u201313.","journal-title":"Surg Obes Relat Dis"},{"key":"1664_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1016613","volume":"13","author":"J Liao","year":"2022","unstructured":"Liao J, Yin Y, Zhong J, et al. Bariatric surgery and health outcomes: an umbrella analysis. Front Endocrinol (Lausanne). 2022;13:1016613.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01664-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:04:33Z","timestamp":1772006673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01664-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1664"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01664-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joana Nicolau has no conflict of interest to declare. Anna L\u00f3pez-Ferrer is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Anna L\u00f3pez-Ferrer was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Anna L\u00f3pez-Ferrer has received grants\/research supports or participation in clinical trials (paid to Institution) from Abbvie, Almirall, Alumis, Amgen, Boehringer Ingelheim, J&J Innovative Medicine,\u00a0Leo-Pharma, Lilly, Novartis, Takeda, UCB and has received honoraria or consultation fees (paid to herself) from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers-Squibb, Galenicum, J&J Innovative Medicine,\u00a0Leo-Pharma, Lilly, Novartis and UCB. Pablo de la Cueva has participated as Consultant, advisory board member, and has received honorary for speaking and participation in clinical trials with the following pharmaceutical companies: Abbvie, Almirall, Astellas, Biogen, Boehringer, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis,Pfizer, Roche, Sanofi, Takeda and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}